Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic & Oncology Target Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP5F1B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP5F1B WT & Mutant Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. Full-length (with MTS) or mature form options. | View ATP5F1B Products |
| Gene Delivery | ATP5F1B Promise-ORF / Lentivirus. Full-length ORF with native mitochondrial targeting sequence for stable cell lines; shRNA for knockdown. | View ATP5F1B Products |
| Benchmark Ab | Anti-ATP5F1B Research Grade Antibody. Recombinant sequence-verified positive control. | View ATP5F1B Products |
| Validator | ATP5F1B siRNA Set. For transient knockdown verification in metabolic assays and specificity checks. | View ATP5F1B Products |
| Related Target A | ATP5F1A (Alpha Subunit). Forms the catalytic α3β3 hexamer; essential for functional reconstitution and selectivity assays. | View ATP5F1A Products |
| Related Target B | ATP5F1C (Gamma Subunit). Regulatory component controlling catalytic activity; allosteric drug target candidate. | View ATP5F1C Products |
| Related Target C | ATP5F1D (Delta Subunit). Stalk subunit critical for structural integrity; synergistic inhibition potential. | View ATP5F1D Products |
| Related Target D | HK2 (Hexokinase 2). Mitochondrial metabolic node partner in glycolytic/OXPHOS crosstalk. | View HK2 Products |
| Related Target E | VDAC1. Mitochondrial membrane partner functionally interacts with ectopic ATP synthase. | View VDAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Proper folding for ATPase activity | Sequence-verified WT and mutant proteins; >95% purity; suitable for α3β3 reconstitution with ATP5F1A. |
| Mitochondrial localization in cell models | Lentiviral ORF retains native mitochondrial targeting sequence (MTS); verified by N-terminal sequencing and IF perinuclear clustering. |
| Off-target against non-mitochondrial ATPases | Highly purified recombinant antigen enables selective counter-screening vs. cytoskeletal ATPases; homolog panel available (ATP1A1, ATP2A2) for SPR/DSF. |
| Cellular validation & specificity | Gene-specific siRNA set for loss-of-function metabolic phenotyping; validated by qPCR. |
| Surface vs. Mitochondrial targeting validation | Lentivirus-mediated stable cell lines to preserve native cell-surface ectopic conformation. |
| Lack of Controls | Clinical Benchmark Antibodies included for reliable assay calibration. |
Live ATP5F1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ATP5F1B-targeted therapeutics is intensifying within preclinical metabolic reprogramming research, with early-stage pipelines exploring small-molecule inhibition, allosteric modulation, and targeted degradation. As a core component of mitochondrial F1Fo-ATP synthase (Complex V), ATP5F1B represents a critical node in oxidative phosphorylation (OXPHOS). Current R&D focuses on exploiting the "reverse Warburg effect" in aggressive tumors, while also investigating ectopic (cell-surface) ATP synthase as a novel target for antibody-based therapies. The next wave of development is pivoting toward highly selective Antibody-Drug Conjugates (ADCs) and mitochondrial-targeted PROTACs (mitoPROTACs) to achieve tissue-specific metabolic disruption while minimizing systemic toxicity. Combination regimens with glycolysis inhibitors (e.g., HK2 inhibitors) and immunotherapies are expected within 2-3 years.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Metabolic Biotechs, Academic Labs | Solid Tumors (OXPHOS-dependent), Drug-resistant Cancers | Enzymatic Inhibition Assay (Need active recombinant ATP5F1B/ATP5F1A complex) |
| Biologics / ADC (Surface Isoform) | Preclinical Discovery Groups, Academic Spin-offs | Solid Tumors (Glioblastoma, Breast Cancer) | Internalization Assay (Need high-purity ECD or full-length context; Lentivirus cell lines for surface expression) |
| PROTAC / Degraders | Emerging Biotech | Oncology, Neurodegeneration | Stable Cell Line Construction (Need lentiviral ORF with MTS for live-cell imaging) |
| Peptide Inhibitors | Research Institutes | Cardiac Ischemia/Reperfusion Injury | Competition Binding Assay (Need full-length conformational protein) |
| Allosteric Modulators | Pharma Discovery | Type 2 Diabetes, Mitochondrial Disorders | Thermal Shift Assay (Need stable mutant proteins for binding validation) |
Molecular Differentiation & Assay Strategy
Achieving best-in-class targeting of ATP5F1B requires differentiation across these dimensions:
1. Affinity & Selectivity
The catalytic nucleotide-binding domain of ATP5F1B is homologous to other P-loop NTPases (e.g., myosin, kinesin, Na+/K+-ATPase). Off-target inhibition can cause severe toxicity.
- Assay Need: High-purity ATP5F1B/ATP5F1A (α3β3 complex) enzyme inhibition assay (Malachite Green or ADP-Glo); counter-screen panel including ATP1A1, ATP2A2, and cytoskeletal ATPases.
- TarMart Solution: Sequence-verified WT and mutant proteins (>95% purity) for complex reconstitution; homolog panel available.
2. Delivery & Subcellular Localization
The mitochondrial double membrane barrier requires specific lipophilic cation properties or targeted delivery systems.
- Assay Need: Mitochondrial co-localization (Tom20 IF), membrane potential (TMRE), Seahorse XF (OCR/ECAR) analysis.
- TarMart Solution: Lentivirus with native N-terminal MTS (verified by sequencing) for stable cell lines ensuring correct mitochondrial matrix localization.
3. Mechanism: Inhibition vs. Degradation
Small molecules must be distinguished between catalytic inhibition and protein destabilization; PROTACs need E3 ligase recruitment validation.
- Assay Need: SPR/BLI binding kinetics, ITC thermodynamics; siRNA knockdown phenocopy to confirm on-target effects.
- TarMart Solution: ATP5F1B siRNA set for target validation and off-target exclusion; stable cell lines for live-cell imaging.
4. Safety & Therapeutic Window
Complete inhibition of ATP synthase is inherently toxic to high-energy-demand tissues (heart, neurons, retina).
- Assay Need: iPSC-derived cardiomyocyte mitochondrial toxicity panel; normal tissue cross-reactivity screening (for surface-targeting modalities).
- TarMart Solution: High-purity recombinant antigen for developing specific ELISA/SPR binding assays to exclude off-tissue cross-reactivity.